comparemela.com

Latest Breaking News On - Anna protopapas - Page 6 : comparemela.com

Mersana Therapeutics, Inc (NASDAQ:MRSN) Receives $14 71 Average PT from Analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) have been given an average rating of “Buy” by the eight brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock […]

United kingdomAnna protopapasUpifitamab rilsodotin upriMikhail papisovBrian deschuytnerMarshall waceSecurities exchange commissionNuveen asset managementJpmorgan chase coMersana therapeutics incMersana therapeuticsGet ratingExchange commissionStreet corpMontreal canAsset management

Mersana Therapeutics (NASDAQ:MRSN) Trading 4 7% Higher

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)’s stock price traded up 4.7% during mid-day trading on Thursday . The stock traded as high as $4.48 and last traded at $4.48. 1,401,726 shares were traded during mid-day trading, an increase of 7% from the average session volume of 1,304,263 shares. The stock had previously closed at […]

United kingdomBrian deschuytnerAnna protopapasMikhail papisovUpifitamab rilsodotin upriMersana therapeutics company profileVirtu financialAdvisors incSecurities exchange commissionMersana therapeutics incLife insurance coJpmorgan chase coMersana therapeuticsGet ratingExchange commissionUpifitamab rilsodotin

Mersana Therapeutics (MRSN) Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

Mersana Therapeutics (MRSN) Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Anna protopapasDrug administrationMersana therapeutics incChief executive officer

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomJason fredetteAnna protopapasExchange commissionDrug administrationMersana therapeutics incChief executive officerMersana therapeuticsmersana therapeuticsLooking statementsthisPrivate securities litigation reform actAnnual reportMersana therapeutics

U S FDA places Mersana s cancer drug trial on hold following death

(Reuters) - Mersana Therapeutics Inc said on Monday the U.S. drug regulator had placed on hold an early-stage trial testing its experimental cancer dr.

Khushi mandowaraSriraj kalluvilaLeroy leoAnna protopapasMersana therapeutics incExecutive officer anna protopapas

vimarsana © 2020. All Rights Reserved.